Research Topics
Species | David R SpriggsSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group StudyDavid R Spriggs
Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:4466-71. 2007..This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC)...- Optimal sequencing in the treatment of recurrent ovarian cancerDavid Spriggs
Departmental Chemotherapy Service, Memorial Sloan Kettering Center and Cornell Weill Medical College, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 90:S39-44. 2003..The hematologic toxicities associated with topotecan can also be reduced by adjusting the dose and schedule. Prolonged use of topotecan may be feasible and potentially beneficial in some patients... - Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapyMario M Leitao
Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 91:123-9. 2003..The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy... 
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatmentRoisin O'Cearbhaill
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 116:326-31. 2010....- Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian
Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:1082-8. 2007..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated... - A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 110:140-5. 2008..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer... - Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Cancer 118:3703-9. 2012..The objective of the current study was to examine whether BRCA1-associated and BRCA2-associated ovarian cancers were associated with different outcomes... - Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancerJason A Konner
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 29:4662-8. 2011..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed... - BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancerRachel N Grisham
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer 119:548-54. 2013..In the current study, the authors sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer... - Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA
Gynecol Oncol 126:224-8. 2012..BRCA-associated and sporadic ovarian cancers have different pathologic and clinical features. Our goal was to determine if BRCA mutation status is an independent predictor of residual tumor volume following primary surgical cytoreduction... 
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remissionAlexia Iasonos
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Gynecol Cancer 22:63-9. 2012..We illustrate how the duration of second-line therapy (SLT), the time on the investigational therapy (IT), and patient enrollment plan can affect efficacy measures from maintenance trials and might result in underpowered studies...- Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective studyMika A Sovak
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 103:451-7. 2006..CONCLUSION: TC is a well tolerated, active regimen in the treatment of resected, high-risk stage III and IV endometrial cancer that warrants further investigation... - Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsWilliam P Tew
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:358-66. 2010..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent... - Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trialMartee L Hensley
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2824-31. 2002..The median time to progression was 5.6 months (range, 4 to 10 months). CONCLUSION: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS... - Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:2740-8. 2008..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission... - Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerPaul J Sabbatini
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:4170-7. 2007.... - Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang
Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Mod Pathol 23:1104-12. 2010..B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas... - Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphomaJason Konner
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 30:2294-302. 2012..To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma... - Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinomaRobert A Soslow
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Mod Pathol 25:625-36. 2012..60 (95% CI, 0.32-0.84) and a negative predictive value of 1.0 (95% CI, 0.63-1.0)). These preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas... - Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergyDon S Dizon
Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Gynecol Oncol 84:378-82. 2002..Routine retreatment of carboplatin-allergic patients with cisplatin in the relapsed setting cannot be recommended without careful consideration of potential risks and benefits... - Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agentsThapi D Rao
Laboratory of Clinical Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Mol Cancer Ther 10:1939-48. 2011..The isogenic, dual-color fluorescence strategy is an innovative approach that can effectively identify novel drug candidates, selectively targeting cancer cells that have unique molecular properties... - Early detection and prognosis of ovarian cancer using serum YKL-40Jakob Dupont
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:3330-9. 2004..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer... - A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesCarol Aghajanian
The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:2505-11. 2002..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies... - Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumorsLuis H Camacho
Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell Medical Center, New York, New York, USA
Invest New Drugs 25:131-8. 2007..However, despite their potential anti-cancer properties, several pharmacodynamic aspects remain unknown... - Non-kinase second-messenger signaling: new pathways with new promiseGregory M Springett
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Bioessays 26:730-8. 2004.... - Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigenAlena A Chekmasova
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:3594-606. 2010.... - Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16Thapi Dharma Rao
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Appl Immunohistochem Mol Morphol 18:462-72. 2010..Development of such antibodies may be useful for the characterization of MUC16 biology and allow for future studies in targeted therapy and diagnostics... - A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studiesAlexia Iasonos
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Trials 5:465-77. 2008..From a practical perspective, clinicians are interested in designs that can estimate the MTD using fewer patients for a fixed number of doses, or can test more dose levels for a given sample size... - Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancerDon S Dizon
Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
J Clin Oncol 20:1238-47. 2002..This should form the basis of a randomized trial to determine the best agents for initial treatment of relapse from EOC in potentially platinum-sensitive patients... - The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trialsAlexia Iasonos
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Clin Cancer Res 18:5179-87. 2012.... - A phase I trial of perillyl alcohol in patients with advanced solid tumorsChristopher G Azzoli
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer Chemother Pharmacol 51:493-8. 2003..This phase I trial was conducted to determine the optimal dose of perillyl alcohol... - Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 18:6497-508. 2012.... - Genomic complexity and AKT dependence in serous ovarian cancerAphrothiti J Hanrahan
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10471, USA
Cancer Discov 2:56-67. 2012.... - Inclusion of patients with brain metastases in phase I trials: an unmet needMrinal M Gounder
Developmental Therapeutics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Cancer Res 17:3855-7. 2011..Tsimberidou and colleagues demonstrate that selected patients can be appropriately enrolled in phase I trials and have outcomes representative of the general cancer population... - Consolidation for ovarian cancer in remissionPaul Sabbatini
J Clin Oncol 24:537-9. 2006 - Cancer screening: how good is good enough?Martee L Hensley
J Clin Oncol 22:4037-9. 2004